Immunotoxins: Targeted Toxin Delivery for Cancer Therapy

Xin Mei1,2 Junsheng Chen3,4 Jing Wang3,4 Jianwei Zhu1,2,3,4

1 Jecho Laboratories, Inc. Maryland, United States
2 Jecho Biopharmaceuticals Co., Ltd., Tianjin, China
3 Engineering Research Center of Cell and Therapeutic Antibody, MOE, China
4 School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China


Address for correspondence Jianwei Zhu, PhD, MBA, Shanghai Jiao Tong University, 800 Dong Chuan Rd, Shanghai 200240, China (e-mail: jianweiz@sjtu.edu.cn).

Abstract

Immunotoxins are proteins that consist of a protein toxin conjugated to a specific targeting moiety. The targeting moiety is usually an antibody or ligand, such as monoclonal antibody, antibody fragment, a cytokine, or a growth factor. The toxins usually come from plant toxins, bacterial toxins, or human-origin cytotoxic elements. Nearly all toxins work by enzymatically inhibiting protein synthesis. After binding to antigens or receptors on target cell surfaces, immunotoxins are internalized and translocated to the cytosol where they can kill the cells. Immunotoxins have demonstrated high cytotoxicity to cancer cells and to date two immunotoxins have been approved by U.S. Food and Drug Administration on the markets for the treatment of hematological tumors: Lumoxiti and Ontak. Many other molecules are under development or clinical trials for different forms of cancer. Although immunotoxins exhibit great potency in xenograft model systems and early clinical trials, there are obstacles that limit successful treatments, including immunogenicity, nonspecific toxicity, and poor penetration. However, efforts are underway to address these problems. In this review, we summarize immunotoxins currently in clinical trials for either hematological tumors or solid tumors, outline the design of immunotoxins utilizing variety of components, and discuss the prominent examples of redesigned immunotoxins with reduced immunogenicity and nonspecific toxicity, as well as the strategies in manufacturing immunotoxins. With further improvements, it is anticipated that immunotoxins will play an increasing role in cancer therapy.

Keywords ► cancer ► immunotherapy ► immunotoxin ► protein toxin ► antibodies ► immunogenicity ► nonspecific toxicity

Introduction

Over a century ago, Paul Ehrlich proposed the “Magic bullet theory of targeted therapy.” He postulated that if a compound could be made that selectively targeted a disease-causing organism, then a toxin for that organism (in patients) could be delivered along with the agent of selectivity. The hybridoma technology introduced by Kohler and Milstein in 1975 enabled the production of monoclonal antibodies (mAbs) in a large scale.1 Fundamental knowledge gained on cancer antigens or receptors, the structures and mechanisms of mAbs as well as the achievements in recombinant DNA techniques and developments in modern protein engineering trigger people’s interest in developing novel antibody-based cancer therapies, including new mAb constructs2,3 and antibody–cytotoxic agent conjugates,4 including immunotoxins.5,6

In the past 20 years, the development of cancer therapeutic drugs was mainly focused on the field of mAbs. Despite the significant efficacy of mAbs, cancer is still far away from being completely cured. Therefore, many innovative biotherapeutics, which were safer and more effective, were developed to treat tumors in laboratories and clinics. In recent years, bispecific antibodies,7,8 immunotoxins,5,6 oncolytic viruses,9 and antibody–drug conjugate (ADC) drugs4 have gradually
Immunotoxins are proteins that consist of a protein toxin fused to a specific targeting moiety. Antibodies, antibody fragments, or growth factors are employed as targeting moieties. The toxin partners usually come from plants, bacteria, or human-origin cytotoxic elements, which act through enzymatically inhibiting protein synthesis. Many cases demonstrated the potential applications of immunotoxins in preclinical and clinical trials. To improve tumor penetration capacity, some immunotoxins are constructed by fusing a single-chain variable fragment (scFv) or single-domain antibody to toxins, which can lead to enhanced antitumor efficacy when they are delivered intrathecally or intratumorally. Compared with ADC molecules, most immunotoxins can be directly expressed as a fusion protein in host cells, which reduces the off-target effects caused by unstable junctions. The off-target side-effect, that toxins released from the delivery vehicles and bind to normal tissue before getting to target cells, led to unexpected cellular necrosis.

Immunotoxins for Cancer Therapy

There have been more than 70 mAbs on the market and most of which are for cancer therapy. However, to enhance effectiveness of the targeted therapy, one design from logical thinking would be immunoconjugates with cytotoxic agents. The cytotoxic agents may be a chemotherapeutic drug, a protein toxin, or a radionuclide, thus creating ADCs, immunotoxins, or radioimmunoconjugates (RICs), respectively.

An immunoconjugate consists of three essential components: a target portion conjugated via a short spacer to a cytotoxic agent. The most important component of immunoconjugates is the targeting moiety, usually an antibody or cytokine. An ideal antibody should deliver and enhance accumulation of the conjugated payloads specifically to the targeted sites. Identification of an appropriate targeted antigen or receptor is the most important step in designing an immunoconjugate. The linker, linking of the payloads to the targeting moiety, and linkage strategy are another aspect that should be intensively considered. Critically, the linker should not affect the affinity with targets and be stable in bloodstream but labile once inside the targeted cells thus releasing the payloads in the active form. A series of regioselective linking techniques have been developed to fulfill this need. The third component of an immunoconjugate is the cytotoxic payloads. Payloads could be a chemotherapy drug, a protein toxin, or a radionuclide.

Antibody–Drug Conjugates

ADCs are molecules containing an mAb conjugated with a cytotoxic drug via a linker. Early ADCs were composed of whole murine antibodies conjugated to a traditional chemotherapeutic drug. These attempts were not successful due to the rapid clearance caused by the nonspecific toxicity to normal cells and tissues, immunogenicity, insufficient anticancer potency of the conjugated cytotoxic agents, and limited internalization, thus the amount of the effector accumulated in the targeted cells was not enough to trigger cell death. With experiences gained from these early explorations, several improvements were introduced in developing new ADCs. To date, there are three ADCs approved. The first approved ADC was gemtuzumab ozogamicin (Mylotarg), a humanized CD33-targeting IgG4 conjugated to calicheamicin via an acid-labile hydrazine linker. It was approved to treat CD33-positive acute myeloid leukemia (AML) in the year 2000 but withdrawn from the market in 2010. Brentuximab vedotin (Adcetris or SGN-35), an anti-CD30 ADC conjugated to the auristatin derivative monomethyl auristatin E (MMAE) through the cleavable valine–citrulline dipeptide (vc) linker, was approved by U.S. Food and Drug Administration (FDA) in August 2011 for the treatment of Hodgkin lymphoma after the failure of autologous stem cell transplant and systematic anaplastic large cell lymphoma (ALCL) after failure of multiagent treatment. Trastuzumab emtansine (Kadcyla), a humanized HER-2-targeted antibody conjugated to maytansinoid via a thioether linker, was the first ADC approved for treating solid tumors. The success of Adcetris and Kadcyla spurred the development of other ADCs targeting different numerous malignancies. To date, there are over 30 ADCs with different indications under development or clinical investigation.

Radioimmunoconjugates

It was well established that a cancer cell was killed when a sufficient high dose of radiation was delivered. By combining the benefit of the specificity of antibodies and the high potency of radiation therapies, researchers developed RICs exhibiting high potency in treating cancers. RICs are mAbs labeled with therapeutic radionuclides which can deliver radiation precisely to the tumor cells or cells with heterogeneously expressed antigens. So far, two RICs targeting CD20 have been approved for treating hematological malignancies, 90Y-ibrutinumab tiuxetan and 131I-tositumomab. Although RICs gained success in treating hematological malignancies, the responses in solid tumors were insufficient, which may due to the poor radiosensitivity of these tumors as well as the inability to deliver sufficient doses to the targets. Optimizations on the antibodies’ uptake could be made to enhance the efficacy of RICs. In the meantime, there are many other RICs in development, including at least 10 candidates for treating solid tumor. These advances give rise to a variety of opportunities in the management of various cancers, where the radionuclide labeled antibodies may be particularly useful in immunospecific phenotypic imaging, e.g., companion diagnostics. Concerning therapeutic applications, RICs have demonstrated their efficacy in the treatment of both hematological malignancies and solid tumors.
chemical conjugation or expressed as a fusion protein. To date, denileukin diftitox [Ontak] and anti-CD22 antibody with PE38 [Lumoxiti] are the two immunotoxins approved on markets. Ontak, approved in 1999, is a fusion protein consisting of an interleukin-2 (IL-2) receptor targeting a portion conjugated to a modified diphtheria toxin (DT), and was used in treating of CD-25 positive cutaneous T cell lymphoma (CTCL). Lumoxiti, approved in 2018, is a fusion protein consisting of disulfide bond stabilized Fv targeting CD22 fused with toxin PE38 to treat hairy cell leukemia (HCL) in clinics. All the immunoconjugates mentioned above are based on the concept of “magic bullet.” By taking the advantage of the target specificity, mAbs, ADCs, immunotoxins, and RICs can selectively deliver cytotoxic agents to the targeted cells and cause the apoptosis of the target cells while minimizing nonspecific toxicity induced by cytotoxic agents.

Mechanism of Cancer Therapy by Immunotoxins

There are quite a few different designs of an immunotoxic molecule, which may have different mechanisms in target cell killing. The function of the targeting moiety is to bind to the corresponding antigen or receptor and trigger endocytosis. After receptor-mediated internalization, the toxin moiety is activated by proteolysis, then exerts cytotoxic activity. Generally cancer cell killing by immunotoxins can be summarized as the following three steps: first, binding to the target cells: the antigen- or receptor-binding domain of the immunotoxin binds to the corresponding antigen or receptor on the surface of the target cells. Second, entering into the target cells: the translocation domain of the immunotoxin promotes the toxin moiety entry into the target cells by endocytosis or transmembrane transport. Lastly, killing the target cells: the catalytic domain of the immunotoxin in the target cell could trigger cell death by inhibiting target cell protein synthesis or activating some important apoptotic proteins. The mechanisms of different toxins are illustrated by Wayne et al as shown in Fig. 1.27

Human toxins are human cytolytic fusion proteins (hCFPs) that cause cell death through an apoptosis pathway. Compared with toxins from bacteria and plants, hCFPs have lower immunogenicity and cytotoxicity, with higher tumor selectivity and infiltration ability. At present, most of the human toxins used in research are granzyme B (GrB) and ribonucleases (RNases). GrB translocates across the lipid membrane together with perforin, then attacking its target substrate to activate the apoptosis pathway. Natural and engineered RNases may degrade tRNA in vivo to terminate protein synthesis that will lead cell death through apoptosis.

Immunotoxins in Clinical Trials

Many immunotoxins were in clinical stages targeting on both hematological tumors and solid tumors. Two immunotoxic drugs were approved by FDA on global markets (Table 1). Different types of leukemia including CTCL, AML, chronic lymphocytic leukemia (CLL), HCL, non-Hodgkin lymphoma (NHL), etc. were treated by several immunotoxins in clinical stages I to III (Table 1) targeting on CD3, CD22, CD25, CD30,
CD33, etc. on B-cells and others. In certain case, for instance, HCL, it is rare disease and no effective medication before HA22 (Lumoxiti) used in clinic.\textsuperscript{28,29} After several years of clinical development, Lumoxiti was finally approved to global market in August 2018.\textsuperscript{29} Up to now, \textit{Pseudomonas} exotoxin A (PE), ricin, DT, and gelonin have been the commonly used toxins in research laboratories and clinical development.

Clinical development for solid tumors would be much more challenged, as it could be much more difficult than targeting hematologic tumors. Tumor tissues are packed tightly and the mass increases rapidly. The patients are less immunosuppressed and more likely to make neutralizing antibodies to the toxin. Many popular molecules for cancer research including mesothelin, epithelial cell adhesion molecule (EpCAM), EGF\textsubscript{VIII}, ErbB\textsubscript{2}, transferrin receptor (TfR), and IL-13R were used as action targets for a variety of cancer diseases such as mesothelioma, lung, head, neck, bladder, breast cancers, glioblastoma, brain, and CNS tumors. Toxin partners used in these studies were similar to those developed in hematological tumors. Although there is no market product approved in this field, several treatment options of glioblastoma have entered late-phase clinical trials,\textsuperscript{42,43} such as VB\textsubscript{4}–845, IL13–PE38QQR, and TfCRM107 (\textit{\textsuperscript{\textgreater} Table 2}).\textsuperscript{42–51} IL-13–PE38QQR (cintredekin besudotox) has entered phase III clinical trials; it has been developed as a specific tumor-targeting agent, which was administered by positive-pressure convection-enhanced delivery directly to brain tissue at risk for residual infiltrating glioblastoma multiforme after tumor resection.\textsuperscript{43}

VB\textsubscript{4}–845 (oportuzumab monatox) is a humanized scFv immunotoxin targeting EpCAM. It is conjugated with a

\begin{table}[h]
\centering
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Immunotoxin} & \textbf{Targeting moiety} & \textbf{Toxic moiety} & \textbf{Target} & \textbf{Type of tumor} & \textbf{Clinical phase} \\
\hline
DAB389IL2 & IL2 & DAB389 & IL2R & CTCL, NHL, CLL, NSLC & Approved for CTCL\textsuperscript{27} \\
HA22 & Anti-CD22 dsFv & PE38 & CD22 & ALL, HCL, NHL, CLL & Approved for HCL\textsuperscript{28,29} \\
LMB-2 & Anti-CD25 scFv & PE38 & CD25 & CLL, CTCL leukemia & Phase II\textsuperscript{55,56,117} \\
DT388 GMCSF & GMCSF & DAB388 & GM-CSFR & AML, CML & Phase I\textsuperscript{117} \\
RFT5-dgA & Anti-CD25 mAb & dgA & CD25 & NHL, CTCL & Phase I, II\textsuperscript{55,56} \\
UCHT1 & Anti-CD3 biFv & DT & CD3 & CTCL, T cell lymphoma & Phase I, II\textsuperscript{118} \\
RF84-dgA & Anti-CD22 Fab & dgA & CD22 & B-NHL & Phase I\textsuperscript{119} \\
K-dgA & Anti-CD30 mAb & dgA & CD30 & HD, NHL & Phase I\textsuperscript{120} \\
HuM195/rGel & Anti-CD33 MAb & Gelonin & CD33 & AML, CML & Phase I\textsuperscript{71} \\
DT388-IL3 & Variant IL3 & DT388 & IL3R & AML, MDS & Phase I, II\textsuperscript{117,121} \\
\hline
\end{tabular}
\caption{Immunotoxins targeting on hematological tumors}
\end{table}

Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CTCL, cutaneous T cell lymphoma; HCL, hairy cell leukemia; NHL, non-Hodgkin lymphoma.
recombinant humanized anti-EpCAM antibody scFv and PE. Once it binds to EpCAM on the surface of cancer cells, it is internalized to the cytoplasm to induce apoptosis. Oportuzumab monatox was granted orphan drug status in 2005 and a fast track qualification in 2018 for the treatment of non-muscle invasive bladder cancer (NMIBC). Currently, the phase III VISTA study (NCT02449239) is evaluating Oportuzumab monatox, the primary endpoint is the complete response rate.

<table>
<thead>
<tr>
<th>Immunotoxin</th>
<th>Toxic moiety</th>
<th>Target</th>
<th>Type of tumor</th>
<th>Clinical phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>SS1P</td>
<td>PE38</td>
<td>Mesothelin</td>
<td>Mesothelioma, head and neck cancer, lung cancer</td>
<td>Phase I, II</td>
</tr>
<tr>
<td>V84–845</td>
<td>PE</td>
<td>EpCAM</td>
<td>Head and neck cancer, squamous cell and bladder cancer</td>
<td>Phase II, III</td>
</tr>
<tr>
<td>MR1–1</td>
<td>PE</td>
<td>EGFRvIII</td>
<td>Malignant brain tumor</td>
<td>Phase I</td>
</tr>
<tr>
<td>TP38</td>
<td>PE38</td>
<td>EGFR</td>
<td>Brain and CNS tumor</td>
<td>Phase II</td>
</tr>
<tr>
<td>Erb38</td>
<td>Erb2</td>
<td></td>
<td>Breast carcinoma</td>
<td>Phase II</td>
</tr>
<tr>
<td>IL13-PE38QQR</td>
<td>PE38</td>
<td>IL13R</td>
<td>Glioblastoma, brain tumors</td>
<td>Phase II</td>
</tr>
<tr>
<td>IL4-PE38KDEL</td>
<td>PE38</td>
<td>IL4R</td>
<td>Brain, CNS, kidney cancers</td>
<td>Phase I, II</td>
</tr>
<tr>
<td>TF-CRM107</td>
<td>DT (CRM107)</td>
<td>TFR</td>
<td>Glioblastoma, brain tumors</td>
<td>Phase I, II</td>
</tr>
<tr>
<td>DAB389-EGF</td>
<td>DT (DAB389)</td>
<td>EGFR</td>
<td>EGFR-expressing carcinoma</td>
<td>Phase I, II</td>
</tr>
</tbody>
</table>

Abbreviations: CNS, central nervous system; EGFR, epidermal growth factor receptor; TFR, transferrin receptor; DD, Ontak (Denileukin Diftitox), Ontak.

Updated information on immunotoxins in clinical trials has been summarized by a number of outstanding recent reviews recently.6,13,14,52,53

**Immunotoxin Classification**

Immunotoxins are proteins consisting of a targeting moiety which can either selectively bind to a target cell and a killing moiety which could kill the targeted cell after internalization. The targeting moiety could be an antibody, antibody fragment, cytokine, or growth factor, while the most potent toxins are different types of enzymatic inhibitors of protein synthesis. A toxin moiety can be derived from bacteria, fungi, plants, or human cells. Therefore, immunotoxins may be classified according to targeting moieties and toxins.

**Immunotoxin Target and Targeting Moieties**

For cancer therapeutics, the goal of antibody-mediated killing is to eliminate the malignant cells. The choice of antibody will depend on the disease target based on results from basic researches. In general, specific antigens or receptors expressed on malignant cells rather than normal vital tissues are appropriate targets. These antigens and receptors should be internalized after antibody binding, ensuring that the toxinline or drug is transported to the cell interior and then separates from the antibody and kills the cell. It is important to note that targeting antigens are not well validated, which is the risk in target selection. The risk is mitigated if the clinical results of targeting an antigen with an mAb are available. The targeting moiety of immunotoxins can be either an antibody (such as mAb, scFv, and single-domain antibody) or a ligand (such as cytokine, growth factor, and hormone peptide) that binds selectively to an antigen or a receptor expressed on the surface of the target cells.

**Cytokine Receptor as a Target and Ligand as a Targeting Moiety**

The IL-2R complex, which consists of three subunits—α (CD25), β (CD122), and γ (CD132)—is expressed on T lymphocytes and natural killer (NK) cells. Ontak is a fusion...
Immunotoxins: Targeted Toxin Delivery for Cancer Therapy

Mei et al.

protein composed of IL-2 fused to the first 388 amino acids of DT. It has IL-2 instead of an Fv; it targets and kills cells in the same manner as an immunotoxin. Ontak binds tightly to the IL-2 but less to the α subunit. (Ontak (Denileukin Diftitox)) was approved for the treatment of CTCL in adults, and its activity has been reported in other hematologic malignancies, including IL-2R-expressing leukemia. The α subunit is mostly overexpressed in T cell malignancies, since newer immunotoxin attempts to bind this lower-affinity IL-2 receptor α subunit (CD25). LMB2 (anti-Tac [Fv]–PE38) is a fusion protein in which the Fv portion of an antibody to CD25, the α chain of the IL-2 receptor, is fused to PE38.

It has been proved that gliomas overexpress IL receptors. Cytokines IL-4 and IL-13 were used to target gliomas since they are overexpressed in tumor cells. IL4-PE toxin was also reported to show antitumor activity in vivo and regression of human glioblastoma tumors, thus leading to the ongoing phase I/II clinical trials.\(^{57}\) Tumor necrosis factor (TNF)-based immunotoxins were developed with antimelanoma antibody (scFvME Li), which showed cytotoxicity in nude mice.\(^{58}\)

**Growth Factor Receptors as Targets**

Growth factor receptors are generally overexpressed in solid tumors, which make them as effective therapeutic targets. ErbB has higher expression levels in many tumors; ErbB2/Her2 was targeted by ScFv (FRP5)–ETA for solid tumors.\(^{58}\) It consists of an N-terminal ScFv, genetically linked to truncated EP. Epidermal growth factor receptor (EGFR) is another growth factor being used widely for solid tumors. Anti-ScFv EGFRvIII-PE38 in an athymic rat model of neoplastic meningeal gliomas was reported to increase median survival. TP-38 is a recombinant chimeric-targeted toxin composed of the EGFR binding ligand TGF-α and PE-38.\(^{59,60}\)

**Tumor-Associated Antigens as Targets**

The tumor-associated surface antigen EpCAM has been used to target solid tumors and has shown regression of large tumor xenografts derived from lung, colon, or squamous cell carcinomas using ScFv against EpCAM with PE. VB4–845 (or oportuzumab monatox, Proxinium) is a recombinant fusion protein that combines the specificity of an anti-EpCAM ScFv with the toxicity of PE 40.\(^{61-63}\) Mesothelin, expressed on mesotheliomas, ovarian, pancreatic, and lung cancers, has been targeted with PE toxin and was found to have a synergistic effect with chemotherapeutic agents in a mice model.\(^{64,49,66}\) One of the more interesting ITs is SS1P or antimesothelin (Fv)–PE38.\(^{44,49}\)

CD3 is widely expressed in T cell malignancies. An anti-CD3 recombinant immunotoxin (RIT), AdmDT390-bisFv (UCHT1), was constructed from a divalent molecule consisting of two single-chain antibody fragments reactive with the extracellular domain of CD3.\(^{65}\) The combination of HD37-dgA and RFB4-dgA (Combotox) has been studied in adults and children with B-lineage hematologic malignancies. In addition to this, a bivalent recombinant diphtheria-based immunotoxin has been developed in which one Fv targets CD19 and the other targets CD22 (DT2219ARL). This agent has shown activity in preclinical models and is in phase 1 testing in adolescents and adults with B-lineage hematologic malignancies including acute lymphoblastic leukemia (ALL).\(^{65-67}\)

CD22 is a lineage-restricted differentiation antigen expressed on B cells and most B cell malignancies. Because it is rapidly internalized after binding, it is an attractive target for immunotoxins and ADCs. HA22 and variants are named in a patent, which claims a method for treating ALL in pediatric patients.\(^{58}\) In addition to CD22, the receptor CD25 has also been targeted to treat various leukemias and lymphomas. Clinical trials of IMTOK25, using immunotoxin of fusion dgA to anti-CD25 on CD25 positive refractory cutaneous T cell NHL and T cell leukemia or lymphoma were completed.\(^{56}\) CD30 is expressed on several types of hematologic tumors, particularly in HL and ALCL. The anti-CD30 mAb cAC10 was conjugated to MMAE through a valine–citrulline peptide linker to make SGN-35 or brentuximab vedotin.\(^{69,70}\) CD33 is expressed on the surface of early multi-lineage hematopoietic progenitors, myelomonocytic precursors, cells of the monocyte/macrophage system, some lymphoid cells, 80 to 90% of cases of AML, and some cases of B cell precursor and T cell ALL. An anti-CD33 immunotoxin consisting of humanized mAb M195 conjugated to recombinant gelonin (HUM-195/rGEL) was tested in a phase I study in adults with myeloid leukemias.\(^{71,72}\)

**Antibody as a Targeting Moiety**

Antibodies including ScFv, single-domain antibody, full-length murine, and humanized antibodies can be used as targeting moieties. In the early stage, the targeting moieties of immunotoxins were mainly murine mAbs, which had limitations in clinical application due to their large molecular weight (MW) and high immunogenicity. So, smaller size targeting moieties such as ScFv, single-domain antibody, and humanized antibody were developed to reduce immunogenicity. The MW of the complete murine mAb is generally approximately 150 kDa, which may be difficult to diffuse and penetrate into the solid tumor cells due to their large MW. So these immunotoxins were often used for hematological tumors. Immunotoxins composed of such full-size mAbs not only have high immunogenicity, but also are difficult to express in host cells, due to their cytotoxicity. Despite all these, many different types of immunotoxins were still widely developed, as they also have several important advantages, such as a long half-life, strong antigen affinity, and low preparation costs.\(^{11}\)

To overcome the shortcomings of the complete murine mAb, researchers used genetic engineering technology to develop ScFv as the targeting moiety, which has smaller MW, and better permeability and stability. The ScFv has a MW of approximately 25 kDa, which is a combination of a light-chain variable fragment (VL) and a heavy-chain variable fragment (VH) via a flexible linker peptide, and the ScFv retains the specificity and affinity like the complete mAb. The ScFv immunotoxins have shown good results in many studies in hematological and solid tumors.

On the basis of ScFv, to further reduce the MW of the targeting moiety of immunotoxins to benefit for fusion expression, researchers designed the single-domain...
antibody which only contains the VH. Its MW is about half of that of ScFv’s, but it retains most of the antigen-binding ability as ScFv. However, with the decrease of the MW, the half-lives of the immunotoxins composed of ScFv or single-domain antibody were shortened and they were quickly eliminated from the body. The reason for using humanized antibody as the targeting moiety is to reduce the immune rejection induced by exogenous antibody. Compared with the murine antibody, humanized antibody reduces immunogenicity and retains the advantages of high affinity and long half-life. However, there still exist the disadvantages of large MW and low permeability. Humanized antibody has been also used as a targeting partner in ADC. As an example, Pfizer’s Mylotarg (gemtuzumab ozogamicin), a conjugate of an anti-CD33 mAb with calicheamicin, was approved for AML in 2000 and reapproved in 2017. Although it is an ADC drug, it is very similar to humanized immunotoxin. It was prepared by a chemical coupling method and using humanized antibody as the targeting moiety.

Immunotoxins with Different Toxins
Protein toxins exhibit high potency when compared with small molecular cell killing agents. It has been shown that one single molecule in the cytosol is sufficient to kill a cell, thus an extremely low concentration was needed. Among the vast protein toxins, three toxins were intensively studied and commonly used in developing immunotoxins: the bacterial toxins PE and DT, and the plant toxin ricin.

Bacterial Toxins
DT and PE are the most widely studied two bacterial toxins. Both PE and DT enzymatically ADP-ribosylate elongation factor-2 (EF-2) in the cytosol. They each catalyze the ADP-ribosylation of histidine-699 of EF-2, which is posttranslationally modified to a diphthamide residue 35. Despite their similar action, PE and DT have quite different amino acid sequences. In fact, PE’s enzymatic domain is near the carboxyl terminus, while DT’s is near the amino terminus. Conversely, PE’s binding domain is near its amino terminus, and DT’s is near its carboxyl terminus. To reduce the nonspecific toxicity, the binding domain of the toxins was usually deleted to prevent their binding to normal cells. Based on the structural and functional studies, the most common truncated form of PE is PE38, which contains the amino acids 253–364 and 381–613, and the derived form PE38KDEL, in which the last four amino acid residues REDL at the C terminus were replaced by KDEL to enhance the translocation to cytosol. For DT, the most commonly used truncated form is DT388 or DAB389, containing the first 388–389 amino acids of DT.

Pseudomonas Exotoxin A
PE, a 613-amino acid peptide, is one of the virulence factors derived from Pseudomonas aeruginosa and could be structurally and functionally separated into three major domains. Domain Ia is composed of residue 1–252 and responsible for cell recognition and binding, while domain II, residue 253–364, is involved in the translocation of the toxin into the cytosol. Domain III (amino acids 405–613), which is located at the C terminus of PE, halts the protein synthesis by inactivating the eukaryotic translation EF-2 by catalytical ADP-ribosylation. The intoxication procedure was elucidated to contain the following steps: the toxin was first processed by carboxypeptidases in plasma to remove the C-terminus residue Lys613 leaving an REDL terminus, then domain I mediated the binding of the processed toxin to the receptor present on the target cell surface and the sequential internalization into the cell via an endosomal pathway; once internalized into the target cell, the toxin undergoes a transient unfolding and a subsequent proteolytic cleavage by furin at domain II and a reduction of a key disulfide bond, then the C-terminal fragment of the toxin was transported to the endoplasmic reticulum (ER) via the binding of the 609–612 REDL terminus to the KDEL receptor, then domain II mediated the translocation of the toxin to the cytosol, and catalyzed the ADP-ribosylation of the residue in EF-2 and eventually caused the cell apoptosis in the cytosol.

Diphtheria Toxin
DT is derived from the pathogen Corynebacterium diphtheriae, which is a single-chain protein containing 535 amino acids. Like PE, DT is composed of three domains, the enzymatic A domain (amino acids 1–193), the binding B domain (amino acids 482–535), and a translocation domain which is located between the A and B domains. DT shares a similar mechanism with PE, which is catalyzing the ADP-ribosylation of the EF-2 and causing the blockage in protein synthesis. More specifically, DT is cleaved outside the cell into two domains at the furin cleavage site, and forms a di-chain protein which is linked by a single disulfide bond. After binding to the target cell and internalized into the endosome, DT undergoes a transient unfolding at a low pH and a key disulfide bond was reduced. Then the active domain of DT is translocated to cytosol through a channel formed by the T domain and ADP-ribosylates the EF-2 and eventually halts the protein synthesis.

Plant Toxins
Plant toxins can be classified into holotoxins and hemitoxins. Holotoxins (also referred to as class II ribosome-inactivating proteins [RIPs]) include ricin, abrin, mistletoe lectin, and modccin. Hemitoxins, or class I RIPs, include pokeweed antiviral protein (PAP), saporin, bryodin 1, boughanin, and gelonin. Holotoxins contain both binding and catalytic domains, whereas hemitoxins contain only the catalytic domain. Both of holotoxins and hemitoxins exert their toxic effects by inactivating the cell’s ribosomes, thus they can work only when their enzymatically active domains enter the cytosol.

Ricin
Ricin as a representative of holotoxins is extracted from the seeds of castor. Natural ricin is a 64-kDa protein that consists of two domains. Domain A can permanently inactivate the ribosome of eukaryotic cells, and domain B can bind to glycoproteins and glycolipids on the cell surface. Ricin can
enter the target cells by endocytosis, then the two domains of ricin are reduced in endosomal vesicles; the domain A is transferred to the cytoplasm, which inactivates the ribosome by removing the base of G4323 in 28S rRNA of the ribosome, permanently inhibits cellular protein synthesis, and leads to cell death. RNases are nontoxic and can promote apoptosis after entering the cell, inhibiting tumor growth by terminating the cell cycle. RNases can be fused to a targeting antibody or ligand to form an immunotoxin that selectively kills tumor cells, showing significant anticancer effects through specific tumor-cell surface antigens. 

The three major types of toxins discussed above, in which bacterial and plant toxins are highly immunogenic in clinical treatment, and the human toxins avoid this problem. As foreign proteins, nonspecific bacterial and plant toxins may induce the neutralizing antibodies when administrated. This results in a short half-life and thus high doses or more rounds are needed. Although many works have been done to mitigate the immunogenicity of these foreign proteins, fully human-origin cytotoxic proteins stand another chance to construct immunotoxins with reduced or eliminated immunogenicity.

**Immunogenicity, Nonspecific Toxicity, and Other Side Effects**

RITs are genetically engineered proteins being developed to treat cancer. In the development of immunotoxins, immunogenicity and nonspecific toxicity are the major obstacles. The plant- or bacterial-derived toxins are foreign proteins that may induce neutralizing antibody formation in patients, thus causing rapid removal of the immunotoxin from the bloodstream, resulting in a decrease in therapeutic effect. The clinical success of RITs in patients with a normal immune system is limited by their immunogenicity. With a balancing act between immunogenicity and therapeutic potency, one approach is to prevent the activation of B cells by mapping and elimination of B cell epitopes. Another approach is to prevent helper T cell activation by interfering with major histocompatibility complex II presentation or T cell recognition. Immunizing mice with RITs that were deimmunized by chemically conjugating the ricin or dgA prepared by reduction to a targeting portion.

**Gelonin**

Gelonin is another plant-derived single-chain RIP (corresponding to the recombinant ricin toxin A [RTA] chain) exhibiting sound cytotoxicity and is applicable in gene manipulation and thus widely used in RIT construction. As a representative of hemitoxins, gelonin is often studied as the toxin moiety of immunotoxins. Gelonin is a single-chain soluble glycoprotein toxin with a MW of approximately 30 kDa extracted from the seeds of the Himalayan plant *Gelonium multiflorum*. Many studies have shown that gelonin can prevent the association of EF-2 with the 60s ribosomal subunit by removing the base of A4324 in 28S rRNA.

**Human Toxins**

Human toxins are hCFPs that also can trigger apoptosis and cause cell death. Compared with heterologous toxins, hCFPs have lower immunogenicity and cytotoxicity, while having higher tumor selectivity and infiltration ability. At present, most of the human toxins used in research are GrB and RNases. 

**Granzyme B**

GrB is a serine protease found in cytoplasmic granules of NK cells and cytotoxic T cells. Due to cytotoxicity with GrB, it was usually expressed as an inactive zymogen form, and the activity was recovered by lysosomal dipeptidase protease to remove two propeptide amino acids, it is expressed as an inactive zymogen form, and can recover activity by lysosomal dipeptidase protease to remove two propeptide amino acids. GrB can enter the cytoplasm of target cells through the pores in the cell membrane, and cause apoptosis by cutting various structural and functional proteins containing Aps-X, Glu-X sites, etc., such as a variety of caspases, BH3 proapoptotic protein. In addition, GrB is the main effector molecule of the granzyme family. It activates the caspase cascade in target cells, which can rapidly cause DNA fragmentation and lead to cell apoptosis. It can also directly migrate to the nucleus, cutting nuclear proteins to promote nuclear apoptosis.

**RNase**

RNases are capable of hydrolyzing phosphodiester bonds in mRNA, rRNA, or tRNA. RNases play a wide-ranging role in cell processes and correspond to different targets at different sites, even to stop the cell process for the survival of the body. RNases are nontoxic and can promote apoptosis by hydrolyzing RNA in the cytosol. As a toxin moiety of the immunotoxin, RNases have better biosafety and only exert cytotoxicity after entering the cell, inhibiting tumor growth by terminating the cell cycle. RNases can be fused to a targeting antibody or ligand to form an immunotoxin that selectively kills tumor cells, showing significant anticancer effects through specific tumor-cell surface antigens. 

Several approaches have been attempted to overcome the problem of immunogenicity without compromising toxin efficacy. Chemically modifying the protein with high MW polyethylene glycol is a common approach to reduce or eliminate immunogenicity. Researchers tried to modify various immunotoxins with PEG and found PEGylation of toxin may result in a modest reduction in immunogenicity with an unaffected cytotoxicity.

Intensive research studies have also been done to improve the PE moiety to produce smaller and less immunogenic PE molecules. HA22 was taken as the parental molecule. By locating the epitope groups and mutating the key amino
acids in the epitope groups in PE. A mutant immunotoxin HA22–8X was constructed. Domain II contains a lot of proteolytic sites. By deleting domain II except for the furin cleavage site, a smaller toxin HA22-LR (lysosome resistant) was constructed. HA22-LR exhibited more cytotoxic activity to CLL samples than HA22, which may due to the resistance to the proteolytic process while trafficking to the ER. New immunotoxins HA22-LR-6X and HA22-LR-8M were then constructed by combining the HA22-LR deletion with immunogenic epitope removal. Both have a further reduced immunogenicity while retaining a high antitumor activity at high doses. Based on this knowledge, Stish et al linked human epidermal growth factor (EGF) and IL-4 to the B cell epitope-deleted PE38 to create a bispecific immunotoxin-targeting mesothelioma. When administrated to a mouse model, the immunogenicity was greatly reduced with no apparent compromises in antitumor activity. Many more of mutants were constructed by Pastan’s laboratory for the purpose of reducing immunogenicity. Human-derived cytotoxic proteins such as Grb or RNase were used to construct immunotoxins to further eliminate the immunogenicity. Engineering a targeting portion to increase the affinity could therefore reduce the nonspecific toxicity. By introducing three amino acid mutations in CDR3 of the heavy chain of the Fv, moxetumomab pasudotox (Lumoxiti) showed a 14-fold increase in affinity and a 50-fold increase in antitumor activity against HCL and CLL cells. As mentioned above, a bispecific antibody can increase specificity by simultaneously binding different targets. Combining this advantage, researchers can further decrease immunotoxin nonspecific toxicity by employing dual targeting moieties. Using the deimmunizing strategy and dual targeting strategy, Valleria et al. developed 2219KDEL7mut, a PE38-derived immunotoxin simultaneously targeting CD19 and CD22 with improved cytotoxic activity.

Although newer versions of immunotoxins are constructed with improved safety and exhibit sound potency in treating various cancers, the dose administrated to achieve efficient therapeutic outcomes is limited, mainly due to the immunotoxin-related side effects. Most commonly reported toxicities against normal cells and tissues are vascular leak syndrome (VLS), hepatotoxicity, and renal toxicity. Several studies have been reported and indicated that VLS may be resulted from the intact toxin to the circulation. In addition, the linkage may not be stable in circulation and would generate unconjugated mAbs which may block the tumor antigen and decrease the antitumor efficacy. The binding domain of the toxin portion was eliminated with the second-generation immunotoxins; however, chemical conjugation was still used to link the two parts, which might not be stable in circulation time. With further rational design and optimization, the third-generation immunotoxins could be constructed to form a fusion protein of a fragment of an IgG and a part of toxin with a binding domain. When it comes to the expression of the constructs, E. coli, yeast, and CHO cell systems could be used to meet different needs. Among these, the E. coli expression system is the most widely employed one, although this system could not correctly fold the protein of interest with a complex structure. Basically, the immunotoxins are expressed in E. coli as inclusion bodies, followed by denaturing and refolding and a further purification process to obtain the final product. By introducing an ammonium sulfate precipitation, a cGMP purification process for preparing MR1–1 and HA22 afforded high yield and acceptable purity. An eukaryotic system with resistance to toxin, e.g., DT, may be used to produce immunotoxins. Based on this theory, several groups developed mammalian-cell immunotoxin-expression strategies to produce immunotoxins without serious toxicity to the host cells. The chloroplast of green algae demonstrates the ability to fold and assemble complex eukaryotic

### Production of Immunotoxins

For the recombinant expression of toxin-based biotherapeutics, a crucial step lies not only in the choice of the production host but also in the accurate design of the fusion proteins. To avoid or limit the toxicity to production host cells without sacrificing a consistent yield, several systems from bacterial to mammalian host cells have been employed. In the early stage, immunotoxins were assembled through chemical conjugation of the toxin molecule with an antibody IgG that could be manufactured in mammalian systems. To avoid complicated manufacturing steps, an E. coli host system has been commonly used for expressing antibody fragment–toxin fusion proteins without chemical conjugation. The fusion proteins were expressed as an inclusion body that can be purified with no toxic activity to the host cells. Due to limitation of protein size, the entire length of IgG would be difficult to be expressed in E. coli compared to a fragment of the IgG. So ScFv, single-domain antibody or other format of small size of the molecules would be logically considered as the targeting partners in the molecular design, which makes it easy to apply the E. coli system to produce the immunotoxins.

Immunotoxins could be historically categorized into three generations, and the construction and production strategy were developed to meet each generation. The first-generation immunotoxins were conjugates consisting of a whole toxin to an intact antibody. The antibody portion and the toxin portion were prepared separately and chemically conjugated in vitro to form the final fusion proteins. The linkage may be a disulfide bond or a nonreducible thioether bond. The problem of the first-generation immunotoxins was the nonspecific toxicity to normal cells resulted from the intact toxin to the circulation. In addition, the linkage may not be stable in circulation and would generate unconjugated mAbs which may block the tumor antigen and decrease the antitumor efficacy. The binding domain of the toxin portion was eliminated with the second-generation immunotoxins; however, chemical conjugation was still used to link the two parts, which might not be stable in circulation time. With further rational design and optimization, the third-generation immunotoxins could be constructed to form a fusion protein of a fragment of an IgG and a part of toxin with a binding domain. When it comes to the expression of the constructs, E. coli, yeast, and CHO cell systems could be used to meet different needs. Among these, the E. coli expression system is the most widely employed one, although this system could not correctly fold the protein of interest with a complex structure. Basically, the immunotoxins are expressed in E. coli as inclusion bodies, followed by denaturing and refolding and a further purification process to obtain the final product. By introducing an ammonium sulfate precipitation, a cGMP purification process for preparing MR1–1 and HA22 afforded high yield and acceptable purity. An eukaryotic system with resistance to toxin, e.g., DT, may be used to produce immunotoxins. Based on this theory, several groups developed mammalian-cell immunotoxin-expression strategies to produce immunotoxins without serious toxicity to the host cells.
proteins, while the machinery of the chloroplast resembles that of a prokaryote, thus it could be used to accumulate eukaryotic toxins. Taking these advantages of algae, Tran et al. produced correctly formed immunotoxins with full bio-activities in vivo and in vitro. 

Due to cytotoxicity by toxins in a variety of cells, immunotoxins with a full length of IgG were normally not expressed in mammalian cells. *Escherichia coli*-based production procedures to produce fragments of antibody fused with a toxin were seen in many cases. However, it was recently reported that a DT-resistant cell line enabled a variety of cell lines robust for production of DT-encoding lentivirus. 

Besides the above-mentioned construction and production strategies, there are quite a few interesting designs of immunotoxin molecules, or new ways to link the toxin with the targeting moiety. Lee et al. constructed an immunotoxin via site-specific conjugation of anti-Her2 IgG with PE24.83. The two proteins were conjugated using a bifunctional linker having dibenzocyclooctyne and maleimide groups. The tras-tuzumab–PE24 conjugate was cytotoxic to Her2-overexpressing cell lines. Researchers utilized split inteins to generate immunotoxins against HER1/2, while Wang et al. reported reduction of nonspecific toxicity of immunotoxin by intein-mediated reconstitution on target cells. Nanobody-based immunotoxins on several targets including CD7, CD38, and VEGFR2 were constructed and tumor-inhibitory effects were evaluated.

**Conclusions**

Immunotoxins are chimeric proteins that combine the advantages of the specificity of the targeting portion and the potent cytotoxicity of protein toxins. And the area of immunotoxin development is in rapid expansion. To date, two immunotoxins, Ontak and anti-CD22 with PE38, have been approved by the U.S. FDA to treat CTCL and HCL. And clinical trials of other immunotoxins have been performed in hematologic malignancies and solid tumors. Immunotoxins could be used as a single agent or in combination with other agents. At present, the truncated forms of bacterial-derived protein toxin PE and DT are the most frequently used toxins for immunotoxin development. These foreign-protein–related immunogenicity will affect the therapeutic outcome by inducing the formation of neutralizing antibodies, especially in solid tumor treatment.

Thus future research efforts will lie on further reducing the immunogenicity or humanizing the toxic moiety or even utilizing full human-origin protein cytotoxins to construct immunotoxins. Further, identifying novel cancer-related antigens or receptors with high specificity and selectivity and mAbs ready to be internalized once bound to the targets is another aspect that should be extensively worked on. Efforts also should be devoted to optimize the constructs’ orientation and MW and the linkage strategies to reduce the nonspecific toxicity to normal tissues and achieve a higher max tolerance dosage to enhance the therapeutic outcome.

Coadministration with other agents such as chemotherapies and immunosuppressors should also be considered to augment the therapeutic outcomes either by increasing cytotoxic activity or reducing immunogenicity. Immunotoxin manufacturing is another issue that should be addressed. A mammalian cell expression system has the capability to produce mAb and its fragments, but it is susceptible to toxins. It can be utilized to produce soluble immunotoxins in a correct form if a split intein mediated protein ligation strategy was introduced. With further improvements, it is envisaged that in the near future immunotoxins will expand the repertoire for treating cancers.

**Conflicts of Interest**

The authors declare no conflict of interest.

**References**

6. Leshem Y, Pastan I. Pseudomonas exotoxin immunotoxins and antitumor immunity: from observations at the patient’s bedside to evaluation in preclinical models. Toxins (Basel) 2019;11(01);E20


Rasala BA, Mayfield SP. The microalgan Chlamydomonas reinhardtii as a platform for the production of human protein therapeutics. Bioeng Bugs 2011;2(01):50–54


